Zogenix to Present at Stifel 2018 Healthcare Conference
07 nov. 2018 08h00 HE
|
Zogenix, Inc.
EMERYVILLE, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
Zogenix to Release Third Quarter 2018 Financial Results and Host Conference Call and Webcast on November 8
01 nov. 2018 08h00 HE
|
Zogenix, Inc.
EMERYVILLE, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
01 oct. 2018 17h07 HE
|
Zogenix, Inc.
EMERYVILLE, Calif., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
Zogenix to Present at LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology
25 sept. 2018 08h00 HE
|
Zogenix, Inc.
EMERYVILLE, Calif., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
04 sept. 2018 16h38 HE
|
Zogenix, Inc.
EMERYVILLE, Calif., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
Zogenix Phase 2 Study Results Published in Epilepsia Show ZX008 Provides Durable Reduction in Seizure Frequency in Patients With Lennox-Gastaut Syndrome
04 sept. 2018 08h00 HE
|
Zogenix, Inc.
67% of Patients Achieved At Least a 50% Reduction in Convulsive Seizures Global Phase 3 Randomized, Controlled Study in LGS Currently Enrolling Patients EMERYVILLE, Calif., Sept. 04, 2018 (GLOBE...
Zogenix Announces New Data on Psychological and Socioeconomic Impact of Dravet Syndrome and Other Epileptic Encephalopathies at 13th European Congress on Epileptology
30 août 2018 08h00 HE
|
Zogenix, Inc.
EMERYVILLE, Calif., Aug. 30, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
Zogenix Prices Public Offering of Common Stock
07 août 2018 18h21 HE
|
Zogenix, Inc.
EMERYVILLE, Calif., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...
Zogenix Announces Proposed Public Offering of 6,000,000 Shares of Common Stock
06 août 2018 17h14 HE
|
Zogenix, Inc.
EMERYVILLE, Calif., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...
Zogenix Provides Corporate Update and Reports Second Quarter Financial Results
06 août 2018 16h26 HE
|
Zogenix, Inc.
Reported positive top-line results from second pivotal Phase 3 trial of ZX008 in patients with Dravet syndrome, Study 1504 Submission of U.S. and EU regulatory filings for ZX008 in Dravet syndrome...